Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $10.80M
• Dividend Yield: N/A
• Average Volume (3M): 120.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.19
• Revenue Growth: -82.54%
• EPS Growth: -12.53%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -1.23
• Shares Outstanding: 9,799,053
• 10 Day Avg. Volume: 254,335
• 30 Day Avg. Volume: 120,313
• PEG Ratio: <0.01
• Price to Book (P/B): 0.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.21
• Enterprise Value/Market Cap: -2.64
• Enterprise Value/Revenue: -1.57
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: 0.81
• 1Y Price Target: $2.00
• Price Target Upside: 127.27% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 37 Underperform
• Price Target: $1.00 ▲(13.64%Upside)

Hookipa Pharma's stock score is severely impacted by its dire financial performance, negative technical indicators, and unfavorable corporate events. The company's strategic decisions to sell assets and delist from Nasdaq highlight critical challenges, overshadowing any potential strengths. The overall outlook is negative, with substantial risks to investors.

Positive Factors

Corporate Restructuring

Poolbeg shareholders are expected to receive 0.03 shares of Hookipa for each Poolbeg share, resulting in approximately 55% of the equity of the combined entity.

Negative Factors

Financial Stability

Hookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.

Shareholder Dilution

Hookipa plans to raise approximately $30M through a primary private placement, which is expected to lead to significant dilution for current Hookipa shareholders.

Hookipa Pharma Business Overview & Revenue Model

Company Description

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

How the Company Makes Money

Hookipa Pharma generates revenue primarily through collaborations and partnerships with other pharmaceutical companies and institutions. These collaborations often involve upfront payments, milestone payments, and potential royalty payments upon successful commercialization of products. The company also seeks funding through government grants and research contracts to support the development of its proprietary technology and the advancement of its clinical pipeline. As a clinical-stage company, its revenue model is heavily reliant on these strategic partnerships and external funding sources until its product candidates receive regulatory approval and are commercialized.

Hookipa Pharma Financial Statement Overview

Summary

Hookipa Pharma faces substantial financial difficulties across its income statement, balance sheet, and cash flow. With zero revenue in the latest year and persistent losses, the company struggles with profitability and revenue generation. While leverage risk is low due to minimal debt, declining equity and cash flow challenges raise concerns over long-term financial health. Significant strategic changes are necessary to improve revenue, control costs, and stabilize cash flows to ensure sustainability.

Income Statement

Hookipa Pharma's income statement reveals a challenging financial performance with zero revenue in 2024, a significant decline from previous years. The gross profit margin is non-existent, and they have substantial negative EBIT and EBITDA margins. The net profit margin is also negative, reflecting ongoing losses. Revenue growth has been inconsistent, with a notable drop in the most recent year. The company's trajectory indicates financial instability and a need for strategic adjustments to improve revenue streams.

Balance Sheet

The balance sheet of Hookipa Pharma shows a moderate level of financial stability. The debt-to-equity ratio is low due to minimal debt, indicating low leverage risk. However, the return on equity is negative, driven by consecutive net losses. The equity ratio is satisfactory, suggesting a capital structure with a higher proportion of equity funding. Despite the low debt levels, the declining equity value and recurring losses raise concerns about long-term solvency and the need for improved operational performance.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows in 2024, further deteriorating from the previous year. The free cash flow to net income ratio and operating cash flow to net income ratio are adverse, reflecting cash outflows exceeding earnings. The free cash flow growth rate is negative, indicating a need for better cash management and operational efficiency. Overall, cash flow constraints pose a risk to sustaining operations without fresh capital infusions.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	43.95M	20.13M	14.25M	18.45M	19.58M
Gross Profit	43.95M	16.58M	10.65M	13.81M	-33.55M
EBITDA	-40.85M	-77.34M	-60.40M	-70.13M	-39.15M
Net Income	-43.50M	-81.58M	-64.92M	-75.67M	-44.08M
Balance Sheet
Total Assets	82.55M	161.34M	170.45M	126.05M	187.82M
Cash, Cash Equivalents and Short-Term Investments	39.68M	117.10M	113.44M	66.91M	143.18M
Total Debt	875.00K	6.56M	6.50M	10.63M	10.51M
Total Liabilities	31.33M	71.48M	67.94M	36.45M	31.69M
Stockholders Equity	51.21M	89.86M	102.52M	89.59M	156.12M
Cash Flow
Free Cash Flow	-77.17M	-61.68M	-25.01M	-78.60M	-41.71M
Operating Cash Flow	-76.98M	-57.52M	-20.00M	-66.02M	-39.34M
Investing Cash Flow	-194.00K	-4.16M	-5.02M	-12.58M	-2.37M
Financing Cash Flow	-1.28M	65.67M	72.27M	-235.00K	73.42M

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.28, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 19.07 is Positive, neither overbought nor oversold. The STOCH value of 7.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
PHGE	44 Neutral	$10.38M	―	-68.18%	―	―	45.24%
PHIO	42 Neutral	$11.18M	―	-76.12%	―	―	81.71%
HOOK	37 Underperform	$10.80M	―	-105.79%	―	-82.54%	-12.53%
KZIA	31 Underperform	$9.37M	―	-3028.18%	―	―	19.58%
WINT	28 Underperform	$8.04M	―	-120.01%	―	―	97.84%
PLRZ	―	$6.41M	―	-57.83%	―	―	―

Hookipa Pharma Corporate Events

Hookipa Pharma Approves Asset Sale and Liquidation

On July 29, 2025, HOOKIPA Pharma Inc. held a special meeting of stockholders where they voted on several significant proposals. The stockholders approved the sale of certain assets to Gilead Sciences, Inc., the liquidation and dissolution of the company, and the potential adjournment of the meeting to solicit additional proxies if needed.

The most recent analyst rating on (HOOK) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.

Hookipa Pharma to Delist from Nasdaq Amid Asset Sale

On July 18, 2025, HOOKIPA Pharma Inc. announced its intention to voluntarily delist its common stock from the Nasdaq Capital Market and deregister under the Securities Exchange Act of 1934. This decision follows an asset purchase agreement with Gilead Sciences, Inc., where Gilead will acquire assets related to HOOKIPA’s HB-400 and HB-500 programs. The delisting and deregistration are part of HOOKIPA’s strategic plan to dissolve and liquidate, pending stockholder approval at a special meeting on July 29, 2025. The move is aimed at reducing compliance costs and maximizing asset distribution to stockholders.

The most recent analyst rating on (HOOK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.

Hookipa Pharma Sells Assets to Gilead Sciences

On May 21, 2025, Hookipa Pharma and its subsidiary entered into an Asset Purchase Agreement with Gilead Sciences to sell assets related to their HB-400 and HB-500 programs. The agreement includes a purchase price of up to $10 million, with $3 million payable at closing and the remainder contingent on a three-phase transfer plan. The transaction requires stockholder approval and involves customary conditions and indemnifications. Additionally, the collaboration agreement with Gilead will terminate upon closing, and the ongoing HB-500 trial will be wound down.

The most recent analyst rating on (HOOK) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.